CABIO BIOTECH (WUHAN) CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.92 CNY | -5.63% |
|
-8.80% | +0.11% |
| 30/04 | Mainland China stocks edge lower ahead of long Labor Day holiday, Hong Kong rises | RE |
| 26/04 | Cabio Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 535M 74.02M 6.18B | Sales 2025 * | 680M 94.12M 7.86B | Capitalization | 3.02B 417M 34.86B |
|---|---|---|---|---|---|
| Net income 2024 * | 117M 16.2M 1.35B | Net income 2025 * | 149M 20.62M 1.72B | EV / Sales 2024 * | 5.64 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 4.44 x |
| P/E ratio 2024 * |
25.7
x | P/E ratio 2025 * |
20.1
x | Employees | 444 |
| Yield 2024 * |
1.51% | Yield 2025 * |
0.86% | Free-Float | 49.98% |
More Fundamentals
* Assessed data
More news
| 1 day | -5.63% | ||
| 1 week | -8.80% | ||
| Current month | -8.80% | ||
| 1 month | +24.62% | ||
| 3 months | +51.99% | ||
| 6 months | -7.44% | ||
| Current year | +0.11% |
1 week
17.70
20.93
1 month
12.0420.93
Current year
9.9820.93
1 year
9.9823.50
3 years
9.9849.50
5 years
9.9849.50
10 years
9.9849.50
| Managers | Title | Age | Since |
|---|---|---|---|
De Wei Yi
CEO | Chief Executive Officer | 59 | 22/04/22 |
Hua Biao Wang
DFI | Director of Finance/CFO | 59 | 22/04/22 |
Zhi Ming Wang
CTO | Chief Tech/Sci/R&D Officer | 55 | 22/04/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jian Ming Yao
CHM | Chairman | 61 | 15/15/15 |
De Wei Yi
CEO | Chief Executive Officer | 59 | 22/04/22 |
Qi Liu
BRD | Director/Board Member | 47 | 27/21/27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/24/10 | 17.92 | -5.63% | 16,656,550 |
| 09/24/09 | 18.99 | -2.11% | 12,659,370 |
| 08/24/08 | 19.4 | -2.22% | 17,856,200 |
| 07/24/07 | 19.84 | -2.02% | 17,104,180 |
End-of-day quote Shanghai S.E., May 10, 2024
More quotes
Cabio Biotech Wuhan Co Ltd is a China-based company principally engaged in biotechnology business. The Company is mainly engaged in the research and development, production and sales of polyunsaturated fatty acids arachidonic acid (ARA), algal oil docosahexaenoic acid (DHA) and sialic acid (SA), and natural beta-carotene products. Its products are mainly used in infant formula food, dietary supplements, nutritional health food and formula food for special medical purposes. The Company integrates industrial strain-oriented optimization technology, fermentation fine control technology, and efficient separation, purification and preparation technology, and provides nutrient products and innovative solutions for customers in the global nutrition and health field through sustainable microbial synthesis and manufacturing methods. The Company mainly conducts its business in domestic and overseas markets.
Sector
Food Processing
Calendar
22/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
17.92
CNY
Average target price
18.5
CNY
Spread / Average Target
+3.24%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +0.11% | 417M | |
| +16.80% | 8.43B | |
| +7.94% | 7.8B | |
| +15.02% | 6.82B | |
| -6.75% | 3.74B | |
| -4.77% | 3.77B | |
| +4.41% | 1.44B | |
| +20.28% | 1.04B | |
| -12.85% | 890M | |
| -15.63% | 812M |
- Stock Market
- Equities
- 688089 Stock